Journal of Alzheimer’s Disease

2019 Editorial Board Update

Editor-in-Chief
George Perry
JAD: Analytics

- Impact factor: **3.517** (Web of Science Group 2019)
- CiteScore: 3.66 (Scopus)
- h-index: 110 (Web of Science) – Highest of any AD journal
- h-index: 115 (SCImago Journal Rank indicator)
- h5-index of 68 (Google Scholar)
- h5-median of 93 (Google Scholar)
- JAD articles have been cited 120,790 times
- 6,904 articles published
- Average citations per item: 17.5
Policies

Author Instructions:

- Policy on the Use of Animals
- Policy on the Use of Human Subjects
- Policy on Ethics
- Financial Disclosures
- Compliance with Major Funding Agencies (including PubMed Central, NIH Public Access, Wellcome Trust and RCUK)
  - Green Open Access Publishing in JAD (Self-Archiving)
  - Gold Open Access Publishing in JAD (Open Access Option EUR1250 / $1450)
Editorial Board Policy:

- Terms of new Associate Editors will begin January 1st of the following calendar year.
- Terms can be extended by one year by performing Acts of Service with a limit of two extensions in any given year. Once this limit has been reached, additional acts of service will be applied to the goal of Senior editorship for that year.
- To elevate to Senior Editor status, an Associate Editor must complete five (5) Acts of Service during a one-year period. Guest editing a Special Issue automatically qualifies the Associate Editor for Senior editorship in the next year.
- Senior Editors are responsible for soliciting and handling review articles and, to maintain status as Senior Editor, must solicit at least two review articles per year as part of their five (5) Acts of Service.
- 75% of corresponding authors accept the Associate Editor invitation.
July 29, 2019

Editorial

Top Reviewers in 2018
Jesus Avila, Suzanne de la Monte, Amos Korczyn, Paula Moreira, Henrik Zetterberg

Editors with the most Acts-of-Service in 2018
Jin-Tai Yu and Ling-Qiang Zhu (14), Patrizia Mecocci (10), Sang Won Seo (8), Jack de la Torre (7)
Citations to JAD (Per Year)

Top 10 journals citing JAD:

1. FRONT AGING NEUROSCI
2. FRONT NEUROSCI
3. SCIENTIFIC REPORTS
4. MOL NEUROBIOI
5. ALZHEIMERS DEMENT
6. INTJ MOL SCI
7. CURR ALZHEIMER RES
8. PLOS ONE
9. ALHEIMERS RES THER
10. NEUROBIOL AGING

From JCR 2019
Articles received and accepted

<table>
<thead>
<tr>
<th>Year</th>
<th>Received</th>
<th>Accepted</th>
<th>Accept Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>2011</td>
<td>797</td>
<td>375</td>
<td>47%</td>
</tr>
<tr>
<td>2012</td>
<td>817</td>
<td>465</td>
<td>57%</td>
</tr>
<tr>
<td>2013</td>
<td>932</td>
<td>457</td>
<td>49%</td>
</tr>
<tr>
<td>2014</td>
<td>1085</td>
<td>599</td>
<td>55%</td>
</tr>
<tr>
<td>2015</td>
<td>1180</td>
<td>629</td>
<td>53%</td>
</tr>
<tr>
<td>2016</td>
<td>1291</td>
<td>715</td>
<td>55%</td>
</tr>
<tr>
<td>2017</td>
<td>1179</td>
<td>698</td>
<td>59%</td>
</tr>
<tr>
<td>2018</td>
<td>1300</td>
<td>672</td>
<td>52%</td>
</tr>
</tbody>
</table>
# Optional Open Access

<table>
<thead>
<tr>
<th>Year</th>
<th>Open Access</th>
<th>Total Articles</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>2012</td>
<td>48</td>
<td>465</td>
<td>10%</td>
</tr>
<tr>
<td>2013</td>
<td>30</td>
<td>457</td>
<td>7%</td>
</tr>
<tr>
<td>2014</td>
<td>55</td>
<td>599</td>
<td>9%</td>
</tr>
<tr>
<td>2015</td>
<td>57</td>
<td>629</td>
<td>9%</td>
</tr>
<tr>
<td>2016</td>
<td>91</td>
<td>715</td>
<td>13%</td>
</tr>
<tr>
<td>2017</td>
<td>122</td>
<td>698</td>
<td>17%</td>
</tr>
<tr>
<td>2018</td>
<td>114</td>
<td>635</td>
<td>18%</td>
</tr>
</tbody>
</table>
Turnaround Time (submission to first decision)

<table>
<thead>
<tr>
<th>Year</th>
<th>2011</th>
<th>2012</th>
<th>2013</th>
<th>2014</th>
<th>2015</th>
<th>2016</th>
<th>2017</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Average (days)</td>
<td>26.5</td>
<td>24.8</td>
<td>24.8</td>
<td>28.1</td>
<td>27.5</td>
<td>27.6</td>
<td>28.1</td>
<td>28.9</td>
</tr>
</tbody>
</table>

Median turnaround time in 2018: 29 days
Average turnaround time (5-year period, 2014-2018): 27.6 days
## Publishing Schedule 2019

**new issue every 2 weeks**

<table>
<thead>
<tr>
<th>Volume</th>
<th>Contents</th>
</tr>
</thead>
</table>
| Volume 67: | Number 4, 2019  
Number 3, 2019  
Number 2, 2019  
Number 1, 2019 |
| Volume 68: | Number 4, 2019  
Number 3, 2019  
Number 2, 2019  
Number 1, 2019 |
| Volume 69: | Number 4, 2019  
Number 3, 2019  
Number 2, 2019  
Number 1, 2019  
Number 1, 2019 Mini-Forum: IMI PharmaCog WP5-  
European ADNI Study |
| Volume 70: | Number 4, 2019  
Number 3, 2019  
Number 2, 2019  
Number 1, 2019  
Supplement 1, 2019 International Research Network on Dementia Prevention |
| Volume 71: | Number 4, 2019  
Number 3, 2019  
Number 2, 2019  
Number 1, 2019 |
| Volume 72: | Number 4, 2019  
Number 3, 2019  
Number 2, 2019  
Number 1, 2019 |
Recent Special Issues:

- Mini-Forum: Multivariate Approaches in Neuroimaging: Assessing the Connectome of Alzheimer's Disease (Guest Editors: Juan Manuel Gómez Sáez, Juan Eugenio Iglesias, Javier Ramírez Pérez de Inestrosa)
- Mini-Forum: The IMI PharmaCog WP5-European ADNI-study: Role of biomarkers to diagnose and track short term disease progression in prodromal Alzheimer's Disease (Guest Editor: Giovanni B. Frisoni)

Upcoming:

- Supplement: International Research Network on Dementia Prevention (Guest Editors: Ruth Peters, Kaarin Anstey)
- Supplement: Gait Disorders in Alzheimer’s Disease and Other Dementias (Guest Editors: Manuel Montero-Odasso and George Perry)
- Handbook: Traumatic Brain Injury and Cognition (Guest Editor: Rudy Castellani)
- Handbook: Air pollution and Alzheimer’s disease (Guest Editor: Lilian Calderón-Garcidueñas)
- Supplement: Epidemiological Aspects of Subjective Cognitive Impairment and Mild Cognitive Impairment: Population-Based Data (Guest Editor: Roberto Monastero)
- Mini-Forum: Mitochondrial dysfunction in Alzheimer’s disease (Guest Editor: Benedict C. Albensi)
- Supplement: Healthy Aging and Dementia Research (Guest Editor: P. Hemachandra Reddy)
Ethics Review
What’s New?

Allyson C. Rosen, ABPP-CN
Ethics Editor
Ethics Section Latest Articles

Editor: Allyson Rosen, PhD

2018
- Perspectives on Communicating Biomarker-Based Assessments of Alzheimer’s Disease to Cognitively Healthy Individuals Milne et al.
- Cognitively Healthy Individuals Want to Know Their Risk for Alzheimer’s Disease: What Should We Do? Stites SD
- Ethical Arguments Concerning the Use of Alzheimer’s Disease Biomarkers in Individuals with No or Mild Cognitive Impairment: A Systematic Review and Framework for Discussion Smedinga et al.

2019
- Ethical Issues in the Treatment of Late-Stage Alzheimer’s Disease Watt et al.
- Are Disease Modifying Treatments Enough? Improving Quality of Life in Late-Stage Patients Rosen et al.
- “To Treat or not To Treat”: Informing the Decision for Disease-Modifying Therapy in Late-Stage Alzheimer’s Disease Watt et al.
- Prioritizing Benefits: A Content Analysis of the Ethics in Dementia Technology Policies Robillard et al.
Disclosure of AD Risk Factors (Biomarkers and Genetic)

- Patients are increasingly receiving their raw data and risk information
  - Direct to Consumer (e.g., 23andMe) disclosures alter how clinicians and clinical researchers interact
  - Widespread use of PET may make amyloid data clinically available
  - Research is increasingly enriching patient groups using these data

- A group assembled to address these and related issues
  - What can we tell patients (what’s the state of science)?
  - Should asymptomatic people receive their data?
  - How should we tell symptomatic patients their results?
  - What are the legal and ethical issues/solutions to this problem?
  - How can we engage a wide network of voices?
Genetic and Biomarker Disclosure Working Group
Co-Chairs – Neelum T. Aggarwal
Carey E. Gleason

Research, Data/Analytic Committee
Chair – Ellen Wijsman

SubComA – Symptomatic Persons
Co-Chairs – Judy Heidebrink, Jennifer Lingler

SubComB – Asymptomatic Persons
Co-Chairs – Deborah Blacker, Malia Rumbaugh

Members/Partners
- Alzheimer’s Assn
- Arizona ADC
- Assn for Frontotemporal Degen.
- B.A.B.E.S
- Banner Alzheimer’s Institute
- Boston U ADC
- Brigham & Women’s/Harvard Med
- Brown University/Butler
- Columbia University
- Emory University
- Indiana University
- Lewy Body Dementia Association
- Mass General ADRC
- Mayo ADRC
- Northwestern Univ Feinberg SOM
- NCRAD
- Rush ADC
- Stanford University
- U C – Irvine ADRC
- UC – San Diego ADRC
- UC – San Francisco
- U of Kentucky
- U of M – ADC
- U of Minnesota
- U of Michigan
- U of Pennsylvania ADC
- U of Pitt – ADRC
- U of Rhode Island
- U of Utah
- U of Wash ADRC
- USC
- Wake Forest School of Medicine
- Washington U – ADRC
- Wisconsin – ADRC
- Amer. Health Lawyers Assn
- NIA/NIH International
- NIA
- FDA

Stakeholder Committee
Chair: Jamie Tyrone
Alzheimer’s Association

Ethics/Healthcare Law Committee
Chair: Robyn Shapiro
Allyson Rosen

Training Committee
Chair: Li San Wang
Briana Vogel
<table>
<thead>
<tr>
<th>Rank</th>
<th>Title</th>
<th>Authors</th>
<th>Times Cited</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Impaired insulin and insulin-like growth factor expression and signaling mechanisms in AD - is this type 3 diabetes?</td>
<td>de la Monte SM et al. (2005)</td>
<td>868</td>
<td></td>
</tr>
<tr>
<td>3.</td>
<td>Insulin and insulin-like growth factor expression and function deteriorate with progression of AD: Link to brain reductions in acetylcholine</td>
<td>de la Monte SM et al. (2005)</td>
<td>383</td>
<td></td>
</tr>
<tr>
<td>4.</td>
<td>Early Clinical PET Imaging Results with the Novel PHF-Tau Radioligand [F-18]-T807</td>
<td>Chien DT et al. (2013)</td>
<td>343</td>
<td></td>
</tr>
<tr>
<td>5.</td>
<td>Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: Relevance to AD</td>
<td>de la Monte SM et al. (2005)</td>
<td>333</td>
<td></td>
</tr>
<tr>
<td>8.</td>
<td>Intracerebral streptozotocin model of type 3 diabetes: Relevance to sporadic</td>
<td>de la Monte SM et al. (2006)</td>
<td>291</td>
<td></td>
</tr>
<tr>
<td>9.</td>
<td>Curcumin interaction with copper and iron suggests one possible mechanism of action in AD animal models</td>
<td>Baum L and Ng A (2004)</td>
<td>287</td>
<td></td>
</tr>
<tr>
<td>Rank</td>
<td>Title</td>
<td>Authors</td>
<td>Cited</td>
<td></td>
</tr>
<tr>
<td>------</td>
<td>-----------------------------------------------------------------------</td>
<td>----------------------------------------------</td>
<td>-------</td>
<td></td>
</tr>
<tr>
<td>1.</td>
<td>Oxidative Stress, Synaptic Dysfunction, and Alzheimer's Disease</td>
<td>Tonnies E and Trushina E (2017)</td>
<td>84</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>(medal winner 2019)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4.</td>
<td>Effects of Regular and Long-Acting Insulin on Cognition and Alzheimer's Disease Biomarkers: A Pilot Clinical Trial</td>
<td>Craft S et al. (2017)</td>
<td>44</td>
<td></td>
</tr>
<tr>
<td>7.</td>
<td>The link between Type 2 Diabetes and Neurodegeneration: Roles for Amyloid-beta, Amylin, and Tau Proteins</td>
<td>Bharadwaj P et al. (2017)</td>
<td>33</td>
<td></td>
</tr>
<tr>
<td>8.</td>
<td>Altered Gut Microbiome Composition and Tryptic Activity of the 5xFAD Alzheimer's Mouse Model</td>
<td>Brandscheid C et al. (2017)</td>
<td>33</td>
<td></td>
</tr>
</tbody>
</table>

First from 2018 at no 12:

<table>
<thead>
<tr>
<th>Rank</th>
<th>Title</th>
<th>Authors</th>
<th>Cited</th>
</tr>
</thead>
</table>
Top 10 Viewed Articles in 2018

3. Moderate-to-High Intensity Physical Exercise in Patients with Alzheimer’s Disease: A Randomized Controlled Trial  Hoffmann K et al. (2016) [Research]
4. Microbes and Alzheimer’s Disease  Itzhaki RF et al. (2016) [Editorial]
10. Postsynaptic Proteome of Non-Demented Individuals with Alzheimer’s Disease Neuropathology  Zolochevska O et al. (2018) [Research] NEW

*via IOS Press Content Website
content.iospress.com/journal-of-alzheimers-disease

NEW in this Listing
Book Series: Advances in Alzheimer’s Disease (AIAD)

- **Vol. 1** Handbook of Animal Models in Alzheimer’s Disease  
  G. Casadesus (Ed.), 2011

- **Vol. 2** Handbook of Imaging The Alzheimer Brain  
  J.W. Ashford, A. Rosen, M. Adamson, P. Bayley, O. Sabri, A. Furst,  
  S.E. Black, M. Weiner (Eds.), 2011

- **Vol. 3** Alzheimer’s Disease: Advances for a New Century  
  G. Perry, X. Zhu, M.A. Smith†, A. Sorensen, J. Avila (Eds.), 2013

- **Vol. 4** Handbook of Depression in Alzheimer’s Disease  
  G.S. Smith (Ed.), 2015

- **Vol. 5** Handbook of Infectious Origin of Alzheimer’s Disease  
  J. Miklossy (Ed.), 2017

- **Vol. 6** Alzheimer’s Disease: New Beginnings  
  G. Perry, J. Avila, P.I. Moreira, A. Sorensen, M. Tabaton (Eds.), 2018

- **Vol. 7** Handbook of Traumatic Brain Injury and Cognition  
  R.J. Castellani (Ed.), In progress

- **Vol. 8** Handbook of Air Pollution and Alzheimer’s Disease  
  L. Calderón-Garcidueñas (Ed.), In progress
Media Coverage

Electrodes wired into the brain could help Alzheimer’s patients, trial finds

Treatments shown to be safe in humans

Music and Meditation Alters Biomarkers of Alzheimer’s and Cellular Aging

Summary: According to researchers, meditation and listening to music may help to alter biomarkers associated with cellular aging and Alzheimer’s disease in adults experiencing memory loss.

Source: JOS Press.

A research team led by Dr. Kim Innes, a professor in the West Virginia University School of Public Health, has found that a simple meditation or music listening program may alter certain biomarkers of cellular aging and Alzheimer’s Disease in older adults who are experiencing memory loss. Study findings, reported in the Journal of Alzheimer’s Disease, also suggest these changes may be directly related to improvements in memory and cognition, sleep, mood, and quality of life.

Poor fitness linked to weaker brain fibre, higher dementia risk

In the largest known brain imaging study, scientists from Costa Mesa, Calif.-based Score Circuits, Google, Johns Hopkins University, the University of California, San Francisco, and UCLA evaluated 62,454 brain single photon emission computed tomography (SPECT) scans of more than 80,000 individuals from 9 months to 105 years of age, to investigate factors that accelerate brain aging. SPECT tomography evaluates regional cerebral blood flow in the brain that is reduced in various disorders.

Largest Known Brain Imaging Study Identifies Drivers of Brain Aging

Published on August 23, 2018

Dietary Supplement May Help Slow Alzheimer’s Progression and Improve Cognitive Outcomes, Small Trial Suggests

Published on September 27, 2018
Top 5 JAD Article Press Releases 2018

Could This Be The Solution For Alzheimer's Disease? = [L+MZ+Z+DHA+EPA] (Jun 2018) – Article: “Nutritional Intervention to Prevent Alzheimer’s Disease: Potential Benefits of Xanthophyll Carotenoids and Omega-3 Fatty Acids Combined” (JAD 64:2)

Ohio State Study of Brain Pacemaker Shows Promise in Slowing Decline of Alzheimer's (Jan 2018) – Article: “Deep Brain Stimulation of Frontal Lobe Networks to Treat Alzheimer’s Disease” (JAD 62:2)

Largest Brain Study of 62,454 Scans Identifies Drivers of Brain Aging (Aug 2018) – Article: “Patterns of Regional Cerebral Blood Flow as a Function of Age Throughout the Lifespan” (JAD 65:4)

Meditation and Music May Alter Blood Markers of Cellular Aging and Alzheimer’s Disease in Adults with Early Memory Loss (Nov 2018) – Article: “Effects of Meditation and Music-Listening on Blood Biomarkers of Cellular Aging and Alzheimer’s Disease in Adults with Subjective Cognitive Decline: An Exploratory Randomized Clinical Trial” (JAD 66:3)

Poor Fitness Linked to Weaker Brain Fiber, Higher Dementia Risk (Feb 2018) – Article: “Cardiorespiratory Fitness and White Matter Neuronal Fiber Integrity in Mild Cognitive Impairment” (JAD 61:2)
Example of Successful JAD Press Release

Article:
“Ohio State Study of Brain Pacemaker Shows Promise in Slowing Decline of Alzheimer’s” Schare et al. (Vol. 62, Iss. 2, 2018)

This press release garnered the article a great deal of exposure. As a result, the study has gained an extremely impressive Altmetric Attention Score of 508 (see below).

The Altmetric Attention Score for a research output provides an indicator of the amount of attention that it has received. The score is derived from an automated algorithm, and represents a weighted count of the amount of attention we’ve picked up for a research output.
Website: J-Alz.com

• Visitors to the website:
  2017: 97K
  2018: 116K

• Traffic to the site increased when press releases were issued relating to new content, plus the press release about anniversary issue (dispatched in May).
Website Features J-Alz.com

Blog:
- Invite experts to write blog content on relevant, topical issues or urgent questions
- Community interaction
- Latest blogs by Ivan Fernández Vega & Silvia Bolognin

Editor’s Choice:
- A recommendation of new high-profile articles as selected by the Editor-in-Chief

Popular Content:
- See what your community is most interested in reading today

Ranking/Awards:
- Alzheimer Award
- The JAD community’s selection of the 50 “game-changing” articles (2006–2015)
- The “Top 100 Investigators in AD” (up to 2009)

CME Credits
- NEW SECTION: Specially selected JAD articles identified for continuing medical education (CME) credits – see more details on next slide

Letters to the Editor:
- Community interaction, encouraging discussion between site users of topics raised in Letters to the Editor

Meta-Objectives:
- Draw readers to the JAD platform
- Help make it a site they will visit every week
- Bring 10 years of key AD research developments together in one place and discuss in community
JAD CME CREDITS

Journal of Alzheimer's Disease Continuing Medical Education (JAD CME)

Test Your Alzheimer's Knowledge With A Quick Quiz for CME Credit!

Launching during AAIC 2019 | Release date: July 15, 2019

Announcing the launch of JAD CME in association with ACEA

Full details at: j-alz.com/cme-credits
The aim is to spread awareness of AD news and highlight JAD content. Sharing articles via social media can have a fantastic reach. A number of Facebook posts in August 2018 reached almost 12K individuals.
Launched in 2018, JAD’s Twitter following increased 10 fold in 1 year. Promoting JAD articles (as well, occasionally, JAD Reports) on Twitter can increase the number of views those articles receive on the IOS Press content site.

**Our aim is to utilize social media to turn likes into JAD article views!**
The best way to keep up to speed about JAD news is to sign up for the newsletter.

Mailings:
- We see JAD’s audience is growing every month
- Average recent engagement level of the JAD newsletter

Tip: There’s always a link to the latest mailing on the JAD website homepage!

Sign up for news: tiny.cc/JADsignup
2019 ALZHEIMER AWARD

JOINT RECIPIENTS:
Yan-Jiang Wang and Xian-Le Bu

for the article
“Gut Microbiota is Altered in Patients with Alzheimer’s Disease”
Journal of Alzheimer’s Disease, 63 (4), 1337–1346, 2018
https://content.iospress.com/articles/journal-of-alzheimers-disease/jad180176

Sponsored by: www.j-alz.com/award
Statement from the winners of the 2019 Alzheimer Award:

Good day!

We are glad that we conducted this interesting study, which suggests that modulation of gut microbiota through personalized diet or beneficial microbiota intervention may be a potential strategy for the prevention and treatment of Alzheimer’s disease. Our study also suggests that Alzheimer’s disease might not be a disease of the brain itself, and brain health is closely associated with our whole body. We need to understand the disease pathogenesis and develop therapies systemically for Alzheimer’s disease and other neurodegenerative diseases.

It is our great honor that our paper is selected for Alzheimer award. We are continuing to study the therapeutic effects of modulating gut microbiota on Alzheimer’s disease. We would like to gratefully acknowledge our co-authors and co-investigators, whose contributions have been essential to the success of this research. We would also like to thank the JAD Editorial Board for selecting our paper from among more than eight hundred excellent articles published by the journal in 2018.

By Yan-Jiang Wang and Xian-Le Bu
Department of Neurology, Daping Hospital, Third Military Medical University, Chongqing, China
Presentation of the 2019 AD Award winner by Editor-in-Chief George Perry, with Weiyi Zeng receiving the award in name of the winners.

The JAD editorial board presentation on July 15 at AAIC 2019

The JAD team in the exhibit hall: fLTR Rasjel van der Holst (Associate Publisher), George Perry (Editor-in-Chief), Carmel McNamara (Marketing Coordinator)
Thank you for your attention!

Any questions? Please contact:
editorial@j-alz.com

Sign up for news: tiny.cc/JADsignup